Possible beneficial impact of surgical deroofing procedure to cover the disadvantage of adalimumab treatment for hidradenitis suppurativa

J Dermatol. 2022 Jan;49(1):e3-e4. doi: 10.1111/1346-8138.16146. Epub 2021 Sep 12.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adalimumab / therapeutic use
  • Hidradenitis Suppurativa* / drug therapy
  • Hidradenitis Suppurativa* / surgery
  • Humans
  • Male
  • Middle Aged
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Adalimumab